Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of associative learning and motor skills by G-CSF and EPO
2005-001113-18Phase 2Terminated
- Sponsor
- Universitätsklinikum Münster
- Start
- Dec 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filgrastim and epoetin alfa in amyotrophic lateral sclerosis (ALS) and stroke (4 arms), sponsored by Universitätsklinikum Münster. Primary endpoints: Improvement in cognitive function (artificial language learning performance) and Improvement in cognitive function (reaction times). Started Dec 2005; status: terminated.
02
Drugs
filgrastimepoetin alfa
03
Conditions
amyotrophic lateral sclerosis (ALS)stroke
Beyond the preview
Go deeper on 2005-001113-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001113-18.